NCT01041040 2013-07-31
LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML)
PETHEMA Foundation
Phase 4 Completed
PETHEMA Foundation
Wyeth is now a wholly owned subsidiary of Pfizer